Nordic Capital related stories
All articles and analysis
Nordic Capital to grow Evosep via organic growth and selective M&ANordic Capital agreed to acquire Evosep, a proteomics tech provider, in mid-November.
Nordic Capital signs deal to acquire Denmark’s EvosepEvosep is a proteomics technology provider for the global life science industry.
The rise and rise of take-privatesShort-term and increasingly passive public markets aren’t always the right fit for major transformations, particularly those being driven by trends such as decarbonisation and AI.
PE investor group to sell clinical trial data firm Clario to Thermo Fisher Scientific for $8.9bnIn addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027.
Nordic Capital to buy financial data and analytics provider BMLLBMLL provides historical trading data and analytics for capital markets.
Nordic's latest flagship target confirmed in US pension fund documentsNordic Capital's Fund XII intends to make equity investments between €250m and €1bn across four key sectors.
Nordic Capital on value creation in good times and badPrivate equity has moved beyond a purely transactional culture, delivering added value and instilling resilience no matter the economic climate, says Nordic Capital’s Peter Thorninger.
The changing face of cost optimisationPrivate equity firms have always focused on cutting costs in portfolio companies. Today, strategies are evolving again to suit a volatile and low-growth environment.
11 PE-backed deals: Positive outlook for Nordic M&AInflexion, Nordic Capital and Main Capital are among the PE firms making deals in the region.
Nordic Capital and Permira make $3bn offer for Bavarian NordicBavarian Nordic is a global vaccine company.